© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
EDITORIAL
Clinical insights and policy adaptations of
COVID-19: lessons learned for future health crises from the Hong Kong Medical Journal and beyond
Claire Chenwen Zhong, PhD, MPhil1,2,3; Junjie Huang, PhD, MSc1,2,3; Harry HX Wang, PhD3,4; Martin CS Wong, MD, MPH1,2,5
1 The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
2 Centre for Health Education and Health Promotion, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
3 Editor, Hong Kong Medical Journal
4 School of Public Health, Sun Yat-Sen University, Guangzhou, China
5 Editor-in-Chief, Hong Kong Medical Journal
Corresponding author: Prof Martin CS Wong (wong_martin@cuhk.edu.hk)

Introduction
COVID-19 epidemic resulted in many remarkable
changes to healthcare systems worldwide. It
challenged clinical practices and public policy
planning at the time with new and distinctive issues.
In this editorial, five dimensions of the pandemic
are discussed: clinical management, variant-driven
shifts, protecting vulnerable populations,
public awareness and behavioural changes, and
healthcare innovation. These elements are essential
to future public health responses because they can
better prepare global healthcare systems to face
other similar emergencies. This editorial provides
a reflective overview of key COVID-19 insights
published in the Hong Kong Medical Journal between
2020 and 2023, along with related literature, to
highlight clinical, public health, and technological
lessons learned during the pandemic.
COVID-19 has substantially reshaped medical
care, population health initiatives, and social norms.
In early 2020, Hong Kong experienced a 28-day
mortality rate of 12.0% among patients with severe
or critical illness.1 Key risk factors for mortality
included advanced age, a history of stroke, use of
renal replacement therapy, and shorter durations
of lopinavir–ritonavir treatment.1 Given the lack
of effective treatments and vaccines at the time,
social distancing and self-isolation became essential
containment strategies.2 3 However, these measures
also led to long-term physical and psychological
consequences, particularly among children.2 Cancer
care was also affected: patients expressed concerns
about delays in treatment development and a lack of
information regarding COVID-19’s impact on their
care.4 Many reported declines in physical, mental, and dietary health due to prolonged isolation.4
Similarly, patients with knee osteoarthritis
experienced more severe symptoms and functional
decline due to reduced access to care and prolonged
inactivity during lockdowns.5
As the virus evolved, so did understanding of its
clinical manifestations, public health implications,
and the role of technology. The pandemic accelerated
the development of artificial intelligence,6 whereas
researchers investigated COVID-19’s diverse
effects—from cutaneous symptoms and autoimmune
responses,7 to the safety of healthcare workers.8 This
article explores five interconnected dimensions of
the pandemic: clinical management, variant-driven
shifts, protection of vulnerable populations, public
awareness and behavioural changes, and healthcare
innovation.
Clinical management
The COVID-19 challenged conventional clinical
management, particularly in severe and atypical
cases. For instance, a patient with COVID-19
presented with severe abdominal and back pain
and was diagnosed with a rare mycotic aortoiliac
aneurysm caused by Salmonella typhimurium.9
Despite controversy surrounding endovascular
stenting in septic conditions, it proved effective
for this critically ill patient.10 In another example,
an immunocompromised patient experiencing
septic shock received high-dose intravenous N-acetylcysteine
to manage an influenza-induced
cytokine storm, highlighting the need for flexible
treatment approaches, especially for those who were
unvaccinated or immunocompromised.11 Unusual
manifestations further complicated diagnosis and care. A 72-year-old woman developed adult-onset
Still’s disease after receiving an mRNA vaccination,
which resulted in myocarditis and cardiogenic
shock.12 Another patient developed autoimmune
myopathy post-infection, with persistent anti–Mi-2
antibodies.13 Additionally, there was an increase in
cases of acute acquired esotropia—a rare form of
strabismus—linked to excessive screen time during
lockdowns.14 These cases underscore the importance
of adaptability in clinical care and the need to
recognise atypical presentations.
The Omicron variant: changing the
pandemic landscape
As the virus evolved, its impact on different
populations also changed, prompting a shift in the
focus of public health. After the Omicron variant
emerged, clinical and public health responses shifted,
marking a critical point in the pandemic. The new
variant was associated with more serious paediatric
cases of croup and a broader range of co-morbidities.
As a result, caregiver stress increased and healthcare
supplies were strained.15 To meet the challenges
posed by the new variant, hospitals had to refine their
facilities, such as nebulisation units. Public health
initiatives adapted to the evolving circumstances.
During Hong Kong’s fifth wave of COVID-19,
mortality rates were high among peritoneal dialysis
patients, a situation attributed to low vaccination
coverage and poor adherence to safety measures,
including handwashing, mask-wearing, and social
distancing.16 These high mortality rates emphasised
the importance of basic hygiene practices, as well
as the necessity of targeted vaccination campaigns.
Shenzhen’s municipal government implemented
targeted interventions by closing schools and
encouraging remote work to prevent transmission.17
These measures, in combination with nucleic acid
testing and optimised screening schemes, played a
key role in the early identification and containment
of cases. Understanding the transmission dynamics
of Omicron is important for public health policies,
which would enable timely protection of vulnerable
populations and the development of tailored
strategies to promote vaccinations.
Protecting the vulnerable through vaccination
Pregnant women, children, older adults, and
individuals with chronic conditions were considered
vulnerable populations and faced disproportionate
risks during the pandemic.18 However, low
vaccination rates were observed among pregnant and
postpartum women in early 2022.19 To address this
issue, hospital-based vaccination teams comprising
obstetricians and midwives were created to provide
personalised support and dispel vaccine-related fears.19 Frailty is a known risk factor for COVID-19
mortality,20 particularly among those aged over 80
years.21 A notable case in Hong Kong involved a
centenarian who survived a breakthrough infection
after completing the Comirnaty vaccine regimen and
receiving a booster shot.20 This example illustrates
the potential benefits of vaccination, even in the
oldest age-groups.
Recent studies have indicated that the gut
microbiome plays a role in predicting responses
to vaccines and adverse events.22 23 A Hong Kong
study demonstrated that the G-NiiB immune
formula is safe for children aged 5 to 17 years.24
It also reduced adverse side-effects from the
vaccine in the experimental group compared with
unvaccinated controls.24 These results may help to
alleviate vaccination concerns among parents and
children. Public health initiatives prioritised at-risk
populations, which in turn influenced societal
behaviours.
Public awareness and behavioural shifts
Public awareness and perception played a pivotal
role in shaping the trajectory of the COVID-19
pandemic. Although prevention is generally more
effective than treatment, the relative impact of
individual preventative measures was unclear
during the early stages.25 Notably, regions with
lower daily case counts usually demonstrated higher
levels of public awareness, suggesting that informed
communities are better equipped to support disease
control efforts.25 Additionally, notable behavioural
shifts were observed. A study by Lin et al26 showed
an increase in unhealthy lifestyles in Hong Kong.
This trend included poorer dietary behaviours and
reduced physical activity, largely due to the shutdown
or restriction of public sports facilities.26 The shift
of education and work to online platforms further
amplified these unhealthy habits. Even in rural
areas, such as western China, students increasingly
experienced eye fatigue and visual impairment due
to prolonged screen use.27 However, there was also a
positive change: smoking and alcohol consumption
decreased, owing to restrictions on social gatherings
and reduced operating hours for bars and clubs.26
These changes reveal how the pandemic broadly
affected society and emphasise the importance of
combining health promotion with public policy. Not
only did behaviours change, tools and technologies
also advanced.
Innovation and the future of healthcare
The COVID-19 pandemic also drove vast innovation
in healthcare, particularly in the realm of digital
health. Telemedicine was crucial for doctors to maintain contact with patients during lockdowns.
However, older adults with limited technological
literacy expressed concerns about difficulties
using the new technology.28 These concerns raised
awareness of the need for government-supported
initiatives to improve technological literacy.28
Although telemedicine played an important role in
bridging gaps in medical care during the pandemic, it
should complement—not replace—conventional in-person
consultations, which facilitate comprehensive
care.28 Other technologies accelerated by COVID-19
included novel diagnostic tools. One example is
volatile organic compound analysers,29 which have
been studied for rapid COVID-19 testing. RNA-sequencing
analysis is another example, employed
to identify differentially expressed genes in severe
and non-severe cases, revealing the mechanisms
underlying lung inflammation and neurological
complications.30 Most recently, artificial intelligence
chatbots powered by large language models have
emerged as a promising asset in healthcare,31
with enormous potential for enhancing practice
management, facilitating patient-physician
interactions, and supporting clinical decision making
in pandemic preparedness and epidemic response.
These developments indicate progress towards
precision medicine and data-driven healthcare. In
the Greater Bay Area, professionals have supported
the adoption of an integrated healthcare model.
This model aims to harness each region’s strengths,
combining Hong Kong’s spirit of compassionate care
with Shenzhen’s technological expertise to create
a synergy capable of addressing complex medical
challenges.32 Looking ahead, standardised data
collection will be crucial to address key questions
regarding COVID-19’s pathophysiology, risk factors,
treatment outcomes, and long-term vaccine safety.6
Although the pandemic posed many complex
challenges to healthcare systems, it also created
opportunities for transformation and long-term
improvement.
Conclusion
The pandemic offered experiences that enabled
Hong Kong to identify and address shortcomings in
its healthcare system. As a result, healthcare experts
were able to strengthen public health planning.
To manage atypical cases, emerging variants, and
evolving societal changes, professionals developed
creative solutions that incorporated flexibility and
innovation. The rapid advancement of technology
and its adoption into the healthcare system
have undoubtedly contributed to alleviating the
COVID-19-related disruptions to the delivery of
medical care. The outcomes and lessons learned
from the pandemic have better equipped healthcare
systems to manage similar public health crises in the
future.
Author contributions
All authors contributed to the editorial, approved the final
version for publication, and take responsibility for its accuracy
and integrity.
Conflicts of interest
The authors are members of the Hong Kong Medical Journal Editorial Board and internal review of this editorial was independently conducted by a senior editor.
Acknowledgement
We acknowledge literature search and review assistance from
Ms Han Wang, Research Assistant at the Jockey Club School
of Public Health and Primary Care, Faculty of Medicine, The
Chinese University of Hong Kong, Hong Kong SAR, China.
References
1. Chan AJ, Lung KC, Yu JS, Shum HP, Tsang TY. Twenty-eight–day mortality among patients with severe or critical
COVID-19 in Hong Kong during the early stages of the
pandemic. Hong Kong Med J 2023;29:383-95. Crossref
2. Leung KK, Hon KL, Ip P, Ng DK. COVID-19 and children:
potential impacts and alleviation strategies. Hong Kong
Med J 2023;29:443-7. Crossref
3. Hon KL, Leung KK, Wang M, Zhao S. COVID-19: evidence
for 2-week versus 3-week quarantine. Hong Kong Med J
2023;29:273-4. Crossref
4. Bao KK, Cheung KM, Chow JC, Leung CW, Wong KH. The
real-world impact of the COVID-19 pandemic on patients
with cancer: a multidisciplinary cross-sectional survey.
Hong Kong Med J 2023;29:132-41. Crossref
5. Khoo J, Chan PK, Wen C, et al. Feasible non-surgical
options for management of knee osteoarthritis during
the COVID-19 pandemic and beyond. Hong Kong Med J
2024;30:56-61. Crossref
6. Wang HH, Li YT, Huang J, Zhang H, Huang W, Wong MC.
COVID-19: emerging trends, healthcare practice, artificial
intelligence–assisted decision support, and implications
for service innovation. Hong Kong Med J 2024;30:7-9. Crossref
7. Wong CS, Hung IF, Kwan MY, et al. Cutaneous
manifestations, viral load, and prognosis among
hospitalised patients with COVID-19: a cohort study.
Hong Kong Med J 2023;29:421-31. Crossref
8. Chan VW, Rahman L, Ng HH, et al. Mitigation of
COVID-19 transmission in endoscopic and surgical
aerosol-generating procedures: a narrative review of early-pandemic
literature. Hong Kong Med J 2023;29:247-55. Crossref
9. So SE, Chan YC, Cheng SW. Successful endovascular
treatment in a COVID-19 patient with mycotic aortoiliac
aneurysm due to Salmonella typhi: a case report. Hong
Kong Med J 2024;30:72-4. Crossref
10. Taylor PR, Chan Y. Endovascular treatment in the
management of mycotic aortic aneurysms. In: Thompson
MM, Morgan RA, Matsumura JS, Sapoval M, Loftus IM,
editors. Endovascular Intervention for Vascular Disease:
Principles and Practice. Boca Raton: Taylor & Francis
Group; 2007: 235.
11. Lai K, Au SY, Sin KC, Yung SK, Leung AK. High-dose N-acetylcysteine
in an immunocompromised patient with
COVID-19: a case report. Hong. Kong Med J 2024;30:69-71. Crossref
12. Kan AK, Yeung WW, Lau CS, Li PH. Adult-onset Still’s
disease after mRNA COVID-19 vaccination presenting with severe myocarditis with acute heart failure and
cardiogenic shock: a case report. Hong Kong Med J
2023;29:162-4. Crossref
13. Plavsic A, Arandjelovic S, Peric Popadic A, Bolpacic J,
Raskovic S, Miskovic R. SARS-CoV-2–associated
myopathy with positive anti–Mi-2 antibodies: a case
report. Hong Kong Med J 2023;29:170-2. Crossref
14. Lau YH, Tang EW, Lai TH, Li KK. Acute acquired esotropia
during the COVID-19 pandemic: four case reports. Hong
Kong Med J 2023;29:165-7. Crossref
15. Lam MC, Lam DS. The Omicron variant of COVID-19 and
its association with croup in children: a single-centre study
in Hong Kong. Hong Kong Med J 2024;30:44-55. Crossref
16. Chow KM, Chan JY, Wong SS, et al. Impact of COVID-19
on the mortality of dialysis patients and kidney transplant
recipients during the Omicron fifth wave in Hong Kong.
Hong Kong Med J 2023;29:82-3. Crossref
17. Zhu B, Han X, Huang J, Gu D. Fighting the Omicron variant:
experience in Shenzhen. Hong Kong Med J 2023;29:79-81. Crossref
18. Wang HH, Guo VY, Xie YJ, Li YT, Huang J, Wong MC.
COVID-19 responses in vulnerable populations: from
clinical management to healthcare policies. Hong Kong
Med J 2024;30:434-6. Crossref
19. Hui P, Yeung LM, Ko JK, et al. COVID-19 vaccination
and transmission patterns among pregnant and postnatal
women during the fifth wave of COVID-19 in a tertiary
hospital in Hong Kong. Hong Kong Med J 2024;30:16-24. Crossref
20. Leung JS. COVID-19 in a centenarian, the vaccination, the
breakthrough infection, and the third booster dose. Hong
Kong Med J 2023;29:181. Crossref
21. Kordowitzki P. Centenarians and COVID-19: is there
a link between longevity and better immune defense?
Gerontology 2022;68:556-7. Crossref
22. Zhang L, Xu Z, Mak JW, et al. Gut microbiota-derived
synbiotic formula (SIM01) as a novel adjuvant therapy
for COVID-19: an open-label pilot study. J Gastroenterol
Hepatol 2022;37:823-31. Crossref
23. Ng SC, Peng Y, Zhang L, et al. Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events. Gut 2022;71:1106-16. Crossref
24. Chow CM, Cheong PK, Hu J, Ching JY. Can a microbiota-derived
health supplement mitigate adverse events after
COVID-19 vaccination in children? Hong Kong Med J
2023;29:542-4. Crossref
25. Mok A, Mui OO, Tang KP, et al. Public awareness of
preventive measures against COVID-19: an infodemiology
study. Hong Kong Med J 2023;29:214-23. Crossref
26. Lin WY, Wong MC, Huang J, Bai Y, Ng SC, Chan FK.
Dietary habits and physical activity during the third wave
of the COVID-19 pandemic: associated factors, composite
outcomes in a cross-sectional telephone survey of a
Chinese population, and trend analysis. Hong Kong Med J
2024;30:33-43. Crossref
27. Ding Y, Guan H, Du K, Zhang Y, Wang Z, Shi Y. Asthenopia
prevalence and vision impairment severity among students
attending online classes in low-income areas of western
China during the COVID-19 pandemic. Hong Kong Med J
2023;29:150-7. Crossref
28. Choi MC, Chu SH, Siu LL, et al. Telemedicine acceptance
by older adults in Hong Kong during a hypothetical severe
outbreak and after the COVID-19 pandemic: a cross-sectional
cohort survey. Hong Kong Med J 2023;29:412-20. Crossref
29. Lai CK, Choi KW, Yao J, Tong RC. Detection of volatile
organic compounds in exhaled breath for mass screening
of COVID-19 infection. Hong Kong Med J 2023;29:175-7. Crossref
30. Li Q, Chen Z, Zhang Y, et al. Genetic association of
COVID-19 severe versus non-severe cases by RNA
sequencing in patients hospitalised in Hong Kong. Hong
Kong Med J 2024;30:25-31. Crossref
31. Andrew A. Potential applications and implications of large
language models in primary care. Fam Med Community
Health 2024;12(Suppl 1):e002602. Crossref
32. Pai PM, Fan JK, Wong WC, Deng XF, Xu XP, Lo CM.
Promoting integrated healthcare for Hong Kong and
Macau residents in the Greater Bay Area during the
COVID-19 pandemic. Hong Kong Med J 2023;29:268-72. Crossref